Get the Stockscreener App
1.20
6.98%
-0.09
After Hours:
1.20
Allakos Inc stock is traded at $1.20, with a volume of 463.30K.
It is down -6.98% in the last 24 hours and up +27.77% over the past month.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
See More
Previous Close:
$1.29
Open:
$1.28
24h Volume:
463.30K
Relative Volume:
0.71
Market Cap:
$107.21M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
-0.6218
EPS:
-1.93
Net Cash Flow:
$-139.92M
1W Performance:
+14.29%
1M Performance:
+27.77%
6M Performance:
+16.50%
1Y Performance:
-54.55%
1-Day Range:
$1.20
$1.38
1-Week Range:
$1.01
$1.38
52-Week Range:
$0.535
$3.36
Allakos Inc Stock (ALLK) Company Profile
Name
Allakos Inc
Sector
Industry
Phone
650-597-5002
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Compare ALLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
1.20 | 107.21M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-17-24 | Downgrade | Jefferies | Buy → Hold |
| Jan-16-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-18-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-08-23 | Resumed | Jefferies | Buy |
| Sep-27-23 | Initiated | JMP Securities | Mkt Outperform |
| May-12-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-07-23 | Initiated | Piper Sandler | Overweight |
| Sep-12-22 | Downgrade | SMBC Nikko | Neutral → Underperform |
| Dec-22-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-21 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-22-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-22-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-15-21 | Initiated | Cowen | Outperform |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Feb-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | BofA Securities | Buy |
| Dec-21-20 | Initiated | SVB Leerink | Outperform |
| Feb-27-20 | Initiated | Barclays | Underweight |
| Feb-04-20 | Resumed | Goldman | Neutral |
| Aug-13-18 | Initiated | Goldman | Neutral |
| Aug-13-18 | Initiated | Jefferies | Buy |
| Aug-13-18 | Initiated | William Blair | Outperform |
View All
Allakos Inc Stock (ALLK) Latest News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - The Eastern Progress Online
BNP Paribas Financial Markets Sells 103,658 Shares of Allakos Inc. (NASDAQ:ALLK) - Defense World
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
Fmr LLC Increases Stock Holdings in Allakos Inc. (NASDAQ:ALLK) - Defense World
Fmr LLC Buys 685,623 Shares of Allakos Inc. (NASDAQ:ALLK) - MarketBeat
Allakos's SWOT analysis: AK006 potential drives stock outlook amid challenges - Investing.com Australia
1,750,000 Shares in Allakos Inc. (NASDAQ:ALLK) Bought by Point72 Asset Management L.P. - MarketBeat
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy - MSN
Allakos Inc. finalizes early lease termination, incurring $2.5 million in costs - Investing.com Canada
Allakos Inc. Alters Lease Agreement for Cost Savings - TipRanks
FMR LLC's Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Allakos's SWOT analysis: biotech firm's stock faces hurdles in CSU market - Investing.com
FY2024 EPS Estimates for Allakos Raised by Leerink Partnrs - MarketBeat
Allakos Runs Up Into A Near-Term Catalyst (NASDAQ:ALLK) - Seeking Alpha
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
10 Health Care Stocks Whale Activity In Today's SessionAllakos (NASDAQ:ALLK), Amgen (NASDAQ:AMGN) - Benzinga
Allakos perks up after early-stage data for lead asset - MSN
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Allakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in October - MarketBeat
3 US Penny Stocks With Market Caps Larger Than $50M - Simply Wall St
Allakos Insiders Miss 24% Gain After Offloading Stock - Simply Wall St
Vernal Keratoconjunctivitis Market Growth to Accelerate - openPR
The Manufacturers Life Insurance Company Sells 2,148 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Short Interest in Custom Truck One Source, Inc. (NYSE:CTOS) Decreases By 5.5% - Defense World
Nasal Polyposis Market Size is Set for Rapid Growth as Innovative - openPR
Chronic Spontaneous Urticaria Market Forecasted to Surge - openPR
Jefferies downgrades Allakos Inc (ALLK) stock to a Hold - Knox Daily
Allakos Inc (ALLK)’s stock price range in the last year - US Post News
Investor’s Delight: Allakos Inc (ALLK) Closes Weak at 0.65, Down -1.14 - The Dwinnex
Allakos shares hold rating after trial update By Investing.com - Investing.com Australia
Piper Sandler maintains Overweight rating on Allakos shares By Investing.com - Investing.com Australia
TD Cowen Reiterates Hold Rating on Allakos Inc. (ALLK) - StreetInsider.com
Piper Sandler maintains Overweight rating on Allakos shares - Investing.com India
Allakos shares hold rating after trial update - Investing.com
Allakos stock gains on trial data for lead drug (NASDAQ:ALLK) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on Allakos Inc. (ALLK) - StreetInsider.com
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - ForexTV.com
Allakos reports positive results from AK006 Phase 1 study - Investing.com India
Allakos Progress Update on AK006 and Future Milestones - TipRanks
Allakos reports positive results from AK006 Phase 1 study By Investing.com - Investing.com UK
Allakos (ALLK) Reports Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - StreetInsider.com
SG Americas Securities LLC Grows Stake in Stellantis (NYSE:STLA) - Defense World
Allakos Inc Stock (ALLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):